Efficacy of hemodiafiltration combined with hemoperfusion in the treatment of secondary hyperparathyroidism
10.3760/cma.j.cn341190-20230519-00428
- VernacularTitle:血液透析滤过串联血液灌流治疗SHPT疗效分析
- Author:
Xiujuan WAN
1
;
Jiamei DI
;
Shu HAN
;
Rong DAI
;
Weinan XIE
;
Yu YAN
;
Yaodi HU
;
Wen FENG
;
Yueyuan CHEN
;
Baohua PENG
Author Information
1. 安徽理工大学第一附属医院肾脏内科，淮南 232007
- Keywords:
Hemoglobins hemidafiltration;
Perfusion;
Renal dialysis;
Hyperparathyroidism;
Parathyroid hormone;
Hemoglobin
- From:
Chinese Journal of Primary Medicine and Pharmacy
2023;30(12):1814-1817
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the efficacy of hemodiafiltration combined with hemoperfusion in the treatment of secondary hyperparathyroidism (SHPT) in patients undergoing maintenance hemodialysis (MHD).Methods:A total of 40 patients with SHPT undergoing MHD who received treatment at the Blood Purification Center of The First Affiliated Hospital of Anhui University of Science and Technology from February 2021 to March 2023 were included in this prospective cohort study. They were randomly divided into a control group and an observation group ( n = 20/group).The control group received a single high flux hemodialysis, while the observation group used a combination of hemodialysis filtration and hemoperfusion for 3 months. In both groups, the changes in hemoglobin, blood urea nitrogen, serum creatinine, serum calcium, serum phosphorus,and parathyroid hormone levels were compared before and after dialysis. Results:After dialysis, the hemoglobin level in the observation group was (119.45 ± 5.27) g/L, which was significantly higher than (106.30 ± 6.52) g/L in the control group ( t = -7.02, P < 0.001). The serum phosphorus level in the observation group was (1.18 ± 0.17) mmol/L, which was significantly lower than (1.52 ± 0.22) mmol/L in the control group ( t = 5.49, P < 0.001). The parathyroid hormone level in the observation group was (122.14 ± 40.57) ng/L, which was significantly lower than (168.78 ± 78.27) ng/L in the control group ( t = 2.39, P = 0.023). Conclusion:Hemodiafiltration combined with hemoperfusion can reduce clinical symptoms, increase hemoglobin level, and reduce phosphorus and parathyroid hormone levels in patients with SHPT undergoing MHD, which deserves clinical promotion.
